Mobile Menu
Deals & Transactions

Conyers advises ShangPharma Corporation on US$173 million privatisation

March 2013 David Lamb Angie Chu

Conyers Dill & Pearman provided Cayman Islands legal advice to the Special Committee in connection with ShangPharma Corporation’s US$173 million privatisation by way of merger with ShangPharma Holdings Limited ("Holdings"), ShangPharma Parent Limited ("Parent") and ShangPharma Merger Sub Limited ("Merger Sub"). As a result of the merger, the Company became a wholly owned subsidiary of Parent.

ShangPharma Corporation (NYSE: SHP) is a leading China-based contract research organization providing high-quality and cost-effective services for the pharmaceutical and biotechnology industry. It offers a broad range of high-quality, integrated services across the drug discovery and development process to help international and Chinese pharmaceutical and biotechnology companies discover and develop novel drug candidates efficiently. The Company's services consist of discovery chemistry, discovery biology and preclinical development, pharmaceutical development and biologics services.

Partner and Co-Chairman David Lamb and Associate Angie Chu of Conyers’ Hong Kong office advised on the matter working alongside O’Melveny & Meyers and Skadden, Arps, Slate, Meagher & Flom.

 


David Lamb
Partner

Hong Kong   +852 2842 9511

Mobile   +852 6469 3377


Angie Chu
Associate

Hong Kong   +852 2842 9549

Mobile   +852 6469 3385


Accolades
_

"Few firms can come close to Conyers on one critical metric, and this is the breadth of the client base."
- IFLR1000

Related Jurisdictions

Cayman Islands


Related International Offices

Hong Kong


Media Contact

For media enquiries, please contact media@conyersdill.com

Deals & Transactions

Conyers advises ShangPharma Corporation on US$173 million privatisation

27 March 2013 David Lamb Angie Chu

Conyers Dill & Pearman provided Cayman Islands legal advice to the Special Committee in connection with ShangPharma Corporation’s US$173 million privatisation by way of merger with ShangPharma Holdings Limited ("Holdings"), ShangPharma Parent Limited ("Parent") and ShangPharma Merger Sub Limited ("Merger Sub"). As a result of the merger, the Company became a wholly owned subsidiary of Parent.

ShangPharma Corporation (NYSE: SHP) is a leading China-based contract research organization providing high-quality and cost-effective services for the pharmaceutical and biotechnology industry. It offers a broad range of high-quality, integrated services across the drug discovery and development process to help international and Chinese pharmaceutical and biotechnology companies discover and develop novel drug candidates efficiently. The Company's services consist of discovery chemistry, discovery biology and preclinical development, pharmaceutical development and biologics services.

Partner and Co-Chairman David Lamb and Associate Angie Chu of Conyers’ Hong Kong office advised on the matter working alongside O’Melveny & Meyers and Skadden, Arps, Slate, Meagher & Flom.

 


David Lamb
Partner

Hong Kong   +852 2842 9511

Mobile   +852 6469 3377


Angie Chu
Associate

Hong Kong   +852 2842 9549

Mobile   +852 6469 3385


 

JURISDICTION(S)

Cayman Islands


International Office(s)

Hong Kong